Global
  • About Us
    Company Profile
    Milestones
    Core Team
  • Science and Technology
    Research Field
    Technology Platform
    Product Pipeline
    Manufacturing Plants
    Intellectual Property Rights
  • Investor Relations
    Company Information
    Financial Reports
    Announcements and Circulars
    Corporate Governance
  • News Centre
    Company News
    Media Coverage
  • Join Us
    Corporate Culture
    Business Outlook
    Benefits
    Job Opportunities
  • Contact us
    Shanghai
    Beijing
    Overseas
NEWS CENTRE NEWS CENTRE
NEWS CENTRE
News Centre
Company News Media Coverage

Year

2023
2022
2021
2020
2019
2018

Month

01
02
03
04
05
06
07
08
09
10
11
12
2023-02-23 10:03
Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901
On 23 February, 2023, Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) and Keymed Biosciences Inc., (“Keymed”) (Stock Code: 02162 HK) today jointly announces a global exclusive licence...
More
  • Pucotenlimab obtains approval for marketing with new achievements | Professor Guo Jun: The approval of pucotenlimab for the new indication of melanoma brings a new treatment option to immunotherapy
    2022-09-30 12:58
    Pucotenlimab obtains approval for marketing with new achievements | Professor Guo Jun: The approval of pucotenlimab for the new indication of melanoma brings a new treatment option to immunotherapy
    More
  • Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication and brings a new treatment option for patients with melanoma
    2022-09-30 09:43
    Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication and brings a new treatment option for patients with melanoma
    More
  • Anti-PD-1 monoclonal antibody Puyouheng (pucotenlimab injection) developed by LEPU BIOPHARMA was approved for marketing by the National Medical Products Administration
    2022-07-22 13:22
    Anti-PD-1 monoclonal antibody Puyouheng (pucotenlimab injection) developed by LEPU BIOPHARMA was approved for marketing by the National Medical Products Administration
    More
  • Lepu Biopharma Completed  Series C Financing
    2021-04-20 15:22
    Lepu Biopharma Completed Series C Financing
    More
  • The IND application of Lepu Biopharma CG0070 Injection was accepted by CDE
    2021-03-05 14:49
    The IND application of Lepu Biopharma CG0070 Injection was accepted by CDE
    More
  • CtM Bio Co., Ltd. and the landing of scientific research cooperation project of Institute of Immunochemistry, Shanghai University of Science and Technology
    2020-10-26 14:43
    CtM Bio Co., Ltd. and the landing of scientific research cooperation project of Institute of Immunochemistry, Shanghai University of Science and Technology
    More
<12>
Home Page
Company Profile
Strategic Investors
Technical Strength
News Centre
About Us
Company Profile
Milestones
Core Team
Science and Technology
Research Field
Technology Platform
Product Pipeline
Manufacturing Plants
Intellectual Property Rights
Investor Relations
Company Information
Financial Reports
Announcements and Circulars
Corporate Governance
News Centre
Company News
Media Coverage
Join Us
Corporate Culture
Business Outlook
Benefits
Job Opportunities
Contact us
Copyright 2021 By Lepu Biopharma CO.,Ltd.
京公网安备11011702000459号京ICP备20018649号-1

Home Page
About Us
Science and Technology
Strategic Investors
News Centre
Join Us
Contact Us